Impact of quality of life on patient expectations regarding phase I clinical trials

Jonathan D. Cheng, James Hitt, Bogda Koczwara, Kevin A. Schulman, Caroline B. Burnett, Darrell Gaskin, Julia H. Rowland, Neal J. Meropol

Research output: Contribution to journalArticle

Abstract

Purpose: Quality of life (QOL) is increasingly recognized as a critical cancer-treatment outcome measure, but little is known about the impact of QOL on the patient decision-making process. A pilot study was conducted in an effort to (1) measure the expectations of patients, physicians, and research nurses regarding the potential benefits and toxicities from experimental and standard therapies, and (2) determine the relationship of QOL to patient perceptions regarding treatment options. Methods: Thirty cancer patients enrolling in phase I clinical trials, their physicians, and their research nurses were administered questionnaires that assessed demographics, QOL, and treatment expectations. Results: Compared with their physicians, patients overestimated potential benefits and toxicities from experimental therapy (mean expected benefit, 59.8% v 23.8%, P <.01; mean expected toxicity, 29.8% v 16.0%, P <.01). Patients estimated a greater potential for benefit (59.8% v 36.8%, P <.01) and less potential for toxicity (29.8% v 45.6%, P = .01) for experimental therapy, compared with standard therapy. Short Form-36 general health perception correlated with patient perception of potential benefit from experimental therapy (r = .48, P = .01). Conclusion: Participants in phase I clinical trial have high expectations regarding the success of experimental therapy and discount potential toxicity. Patient QOL may affect the expectation of benefit from experimental therapy and, ultimately, treatment choice. Understanding the interactions between QOL and patient expectations may guide the development of improved strategies to present appropriate information to patients considering early-phase clinical trials.

Original languageEnglish (US)
Pages (from-to)421-428
Number of pages8
JournalJournal of Clinical Oncology
Volume18
Issue number2
StatePublished - Jan 2000
Externally publishedYes

Fingerprint

Clinical Trials, Phase I
Investigational Therapies
Quality of Life
Physicians
Nurses
Therapeutics
Research
Neoplasms
Decision Making
Demography
Outcome Assessment (Health Care)
Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cheng, J. D., Hitt, J., Koczwara, B., Schulman, K. A., Burnett, C. B., Gaskin, D., ... Meropol, N. J. (2000). Impact of quality of life on patient expectations regarding phase I clinical trials. Journal of Clinical Oncology, 18(2), 421-428.

Impact of quality of life on patient expectations regarding phase I clinical trials. / Cheng, Jonathan D.; Hitt, James; Koczwara, Bogda; Schulman, Kevin A.; Burnett, Caroline B.; Gaskin, Darrell; Rowland, Julia H.; Meropol, Neal J.

In: Journal of Clinical Oncology, Vol. 18, No. 2, 01.2000, p. 421-428.

Research output: Contribution to journalArticle

Cheng, JD, Hitt, J, Koczwara, B, Schulman, KA, Burnett, CB, Gaskin, D, Rowland, JH & Meropol, NJ 2000, 'Impact of quality of life on patient expectations regarding phase I clinical trials', Journal of Clinical Oncology, vol. 18, no. 2, pp. 421-428.
Cheng JD, Hitt J, Koczwara B, Schulman KA, Burnett CB, Gaskin D et al. Impact of quality of life on patient expectations regarding phase I clinical trials. Journal of Clinical Oncology. 2000 Jan;18(2):421-428.
Cheng, Jonathan D. ; Hitt, James ; Koczwara, Bogda ; Schulman, Kevin A. ; Burnett, Caroline B. ; Gaskin, Darrell ; Rowland, Julia H. ; Meropol, Neal J. / Impact of quality of life on patient expectations regarding phase I clinical trials. In: Journal of Clinical Oncology. 2000 ; Vol. 18, No. 2. pp. 421-428.
@article{7f1f2eda4fb84d91a916a2cbc27c4998,
title = "Impact of quality of life on patient expectations regarding phase I clinical trials",
abstract = "Purpose: Quality of life (QOL) is increasingly recognized as a critical cancer-treatment outcome measure, but little is known about the impact of QOL on the patient decision-making process. A pilot study was conducted in an effort to (1) measure the expectations of patients, physicians, and research nurses regarding the potential benefits and toxicities from experimental and standard therapies, and (2) determine the relationship of QOL to patient perceptions regarding treatment options. Methods: Thirty cancer patients enrolling in phase I clinical trials, their physicians, and their research nurses were administered questionnaires that assessed demographics, QOL, and treatment expectations. Results: Compared with their physicians, patients overestimated potential benefits and toxicities from experimental therapy (mean expected benefit, 59.8{\%} v 23.8{\%}, P <.01; mean expected toxicity, 29.8{\%} v 16.0{\%}, P <.01). Patients estimated a greater potential for benefit (59.8{\%} v 36.8{\%}, P <.01) and less potential for toxicity (29.8{\%} v 45.6{\%}, P = .01) for experimental therapy, compared with standard therapy. Short Form-36 general health perception correlated with patient perception of potential benefit from experimental therapy (r = .48, P = .01). Conclusion: Participants in phase I clinical trial have high expectations regarding the success of experimental therapy and discount potential toxicity. Patient QOL may affect the expectation of benefit from experimental therapy and, ultimately, treatment choice. Understanding the interactions between QOL and patient expectations may guide the development of improved strategies to present appropriate information to patients considering early-phase clinical trials.",
author = "Cheng, {Jonathan D.} and James Hitt and Bogda Koczwara and Schulman, {Kevin A.} and Burnett, {Caroline B.} and Darrell Gaskin and Rowland, {Julia H.} and Meropol, {Neal J.}",
year = "2000",
month = "1",
language = "English (US)",
volume = "18",
pages = "421--428",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Impact of quality of life on patient expectations regarding phase I clinical trials

AU - Cheng, Jonathan D.

AU - Hitt, James

AU - Koczwara, Bogda

AU - Schulman, Kevin A.

AU - Burnett, Caroline B.

AU - Gaskin, Darrell

AU - Rowland, Julia H.

AU - Meropol, Neal J.

PY - 2000/1

Y1 - 2000/1

N2 - Purpose: Quality of life (QOL) is increasingly recognized as a critical cancer-treatment outcome measure, but little is known about the impact of QOL on the patient decision-making process. A pilot study was conducted in an effort to (1) measure the expectations of patients, physicians, and research nurses regarding the potential benefits and toxicities from experimental and standard therapies, and (2) determine the relationship of QOL to patient perceptions regarding treatment options. Methods: Thirty cancer patients enrolling in phase I clinical trials, their physicians, and their research nurses were administered questionnaires that assessed demographics, QOL, and treatment expectations. Results: Compared with their physicians, patients overestimated potential benefits and toxicities from experimental therapy (mean expected benefit, 59.8% v 23.8%, P <.01; mean expected toxicity, 29.8% v 16.0%, P <.01). Patients estimated a greater potential for benefit (59.8% v 36.8%, P <.01) and less potential for toxicity (29.8% v 45.6%, P = .01) for experimental therapy, compared with standard therapy. Short Form-36 general health perception correlated with patient perception of potential benefit from experimental therapy (r = .48, P = .01). Conclusion: Participants in phase I clinical trial have high expectations regarding the success of experimental therapy and discount potential toxicity. Patient QOL may affect the expectation of benefit from experimental therapy and, ultimately, treatment choice. Understanding the interactions between QOL and patient expectations may guide the development of improved strategies to present appropriate information to patients considering early-phase clinical trials.

AB - Purpose: Quality of life (QOL) is increasingly recognized as a critical cancer-treatment outcome measure, but little is known about the impact of QOL on the patient decision-making process. A pilot study was conducted in an effort to (1) measure the expectations of patients, physicians, and research nurses regarding the potential benefits and toxicities from experimental and standard therapies, and (2) determine the relationship of QOL to patient perceptions regarding treatment options. Methods: Thirty cancer patients enrolling in phase I clinical trials, their physicians, and their research nurses were administered questionnaires that assessed demographics, QOL, and treatment expectations. Results: Compared with their physicians, patients overestimated potential benefits and toxicities from experimental therapy (mean expected benefit, 59.8% v 23.8%, P <.01; mean expected toxicity, 29.8% v 16.0%, P <.01). Patients estimated a greater potential for benefit (59.8% v 36.8%, P <.01) and less potential for toxicity (29.8% v 45.6%, P = .01) for experimental therapy, compared with standard therapy. Short Form-36 general health perception correlated with patient perception of potential benefit from experimental therapy (r = .48, P = .01). Conclusion: Participants in phase I clinical trial have high expectations regarding the success of experimental therapy and discount potential toxicity. Patient QOL may affect the expectation of benefit from experimental therapy and, ultimately, treatment choice. Understanding the interactions between QOL and patient expectations may guide the development of improved strategies to present appropriate information to patients considering early-phase clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0033971036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033971036&partnerID=8YFLogxK

M3 - Article

C2 - 10637258

AN - SCOPUS:0033971036

VL - 18

SP - 421

EP - 428

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -